Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride PET study in older people with Alzheimer's or schizophrenia
NCT01454453Phase 4Terminated
- Sponsor
- Institute of Psychiatry, Psychology & Neuroscience
- Start
- May 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amisulpride in Alzheimer's disease (AD) and schizophrenia, sponsored by Institute of Psychiatry, Psychology & Neuroscience. Primary endpoint: Dose titration at 12 weeks. Started May 2012; status: terminated.
02
Drugs
amisulpride
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT01454453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01454453.